68.12

3.27% 2.16

After Hours: 65.17 -2.95 -4.33%

Exact Sciences Corp (EXAS)

Overview News Price History Option Chain Financials Discussions Forecast

Exact Sciences Corp stock is traded at $68.12, with a volume of 1.57M. It is up +3.27% in the last 24 hours and up +10.42% over the past month. Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.

Previous Close:

$65.96

Open:

$65.82

24h Volume:

1.57M

Relative Volume:

0.60

Market Cap:

$12.47B

Revenue:

$2.53B

Net Income/Loss:

$-240.23M

P/E Ratio:

-42.96

EPS:

-1.5857

Net Cash Flow:

$-20.46M

1W Performance:

-2.18%

1M Performance:

+10.42%

6M Performance:

-1.36%

1Y Performance:

-0.15%

1-Day Range:

$65.10

$68.17

1-Week Range:

$64.85

$70.39

52-Week Range:

$40.62

$79.62

Exact Sciences Corp Stock (EXAS) Company Profile

Name

Exact Sciences Corp

Sector

Healthcare (1190)

Industry

Diagnostics & Research (58)

Phone

608-284-5700

Address

5505 ENDEAVOR LANE, MADISON, WI

Employee

6,600

Twitter

@exactsciences

Next Earnings Date

2024-10-30

Latest SEC Filings

EXAS's Discussions on Twitter

Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Sep-28-23	Initiated	Bernstein	Outperform
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy
May-05-23	Initiated	UBS	Neutral
Mar-09-23	Upgrade	Citigroup	Neutral → Buy
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Nov-03-21	Downgrade	Raymond James	Strong Buy → Outperform
Jul-29-21	Reiterated	BTIG Research	Buy
Jul-29-21	Reiterated	Canaccord Genuity	Buy
Jul-29-21	Reiterated	Oppenheimer	Outperform
Jul-29-21	Reiterated	Stifel	Buy
Jun-15-21	Initiated	Raymond James	Strong Buy
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Equal Weight
Jan-28-21	Initiated	Truist	Buy
Oct-29-20	Downgrade	UBS	Buy → Neutral
Oct-28-20	Downgrade	Citigroup	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Apr-02-20	Initiated	Evercore ISI	Outperform
Jan-10-20	Resumed	BTIG Research	Buy
Jan-07-20	Initiated	Citigroup	Buy
Dec-13-19	Initiated	Dougherty & Company	Buy
Nov-15-19	Initiated	Stifel	Buy
Oct-17-19	Reiterated	BofA/Merrill	Buy
Oct-01-19	Resumed	Craig Hallum	Buy
Sep-26-19	Initiated	Oppenheimer	Outperform
Feb-26-19	Upgrade	Goldman	Neutral → Buy
Oct-09-18	Initiated	UBS	Buy
Sep-05-18	Resumed	The Benchmark Company	Hold
Aug-13-18	Reiterated	Canaccord Genuity	Buy
Apr-03-18	Upgrade	BTIG Research	Neutral → Buy
Jan-29-18	Initiated	Goldman	Neutral
Jan-08-18	Reiterated	The Benchmark Company	Buy
Nov-13-17	Downgrade	Robert W. Baird	Outperform → Neutral
Nov-01-17	Downgrade	BTIG Research	Buy → Neutral

View All

Exact Sciences Corp Stock (EXAS) Latest News

02:34 AM

Exact Sciences Co. (NASDAQ:EXAS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

02:34 AM

Sep 29, 2024

Exact Sciences Co. (NASDAQ:EXAS) Sees Large Increase in Short Interest - MarketBeat

Sep 29, 2024

Sep 27, 2024

Exact Sciences maintains buy rating despite pricing setback - Investing.com

Sep 27, 2024

Sculptor Capital LP Takes $32.82 Million Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Sep 27, 2024

Sep 26, 2024

Exact Sciences stock Quanterix stocks slip on Medicare rates - Seeking Alpha

Sep 26, 2024

Exact Sciences' stock soars on news that Pfizer will market Cologuard test - WiscNews

Sep 26, 2024

Hsbc Holdings PLC Trims Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Sep 26, 2024

Sep 24, 2024

It makes sense and dollars to buy Exact Sciences Corp. (EXAS) stock - SETE News

Sep 24, 2024

Samlyn Capital LLC Takes $30.43 Million Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Sep 24, 2024

Japan Building 'Zeta-Class' Supercomputer, 1,000 Times Faster Than Today's Fastest Machines - NDTV

Sep 24, 2024

Sep 23, 2024

Profund Advisors LLC Has $3.32 Million Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Sep 23, 2024

From Our Files 09/23/24 - Leader-Telegram

Sep 23, 2024

Sep 22, 2024

Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Elo Mutual Pension Insurance Co - Defense World

Sep 22, 2024

Exact Sciences Co. (NASDAQ:EXAS) Stock Position Boosted by XTX Topco Ltd - MarketBeat

Sep 22, 2024

Sep 20, 2024

Bringing Marketing to a New Audience: Q&A with Jeremy Truxal - Pharmaceutical Executive

Sep 20, 2024

Sep 19, 2024

Exact Sciences Co. (NASDAQ:EXAS) EVP Sells $65,030.00 in Stock - MarketBeat

Sep 19, 2024

Exact Sciences EVP sells shares worth over $65,000 By Investing.com - Investing.com Australia

Sep 19, 2024

Exact Sciences EVP sells shares worth over $65,000 By Investing.com - Investing.com South Africa

Sep 19, 2024

Exact Sciences EVP sells shares worth over $65,000 - Investing.com India

Sep 19, 2024

Exact Sciences EVP sells shares worth over $65,000 - Investing.com

Sep 19, 2024

Exact Sciences EVP sells shares worth over $65,000 By Investing.com - Investing.com UK

Sep 19, 2024

E Fund Management Co. Ltd. Purchases 19,661 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World

Sep 19, 2024